Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 101 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

MRSA Treatment/Vancomycin Resistance

Until recently, the glycopeptides, notably vancomycin, were the mainstay of treatment of infections caused by MRSA; however overuse of vancomycin has led to the emergence of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) strains.
The first reports of S. aureus strains with reduced susceptibility (MIC 4-8 µg/mL) came from Japan in 1997. S. aureus strains with reduced susceptibility have since been reported worldwide.
In 2002, the first strain of VRSA was isolated in the United States in Michigan. As of 2010, four VRSA isolates have been identified in the US. In three of the four cases, a strain of vancomycin-resistant Enterococcus (VRE) was also isolated from the same patient and it is believed that transfer of the vanA gene (like mecA for methicillin, vanA codes for resistance to vancomycin) could have occurred in this setting. The emergence of these strains is alarming because they demonstrate complete vancomycin resistance.